MedWire 
(2/22, Robertson) reports, "The antialbuminuric effect of cilnidipine
is sustained for at least one year during continued treatment in
diabetes patients with normoalbuminuria and microalbuminuria," according
to a
study
published online in Feb. 15 in the journal Diabetes Research and
Clinical Practice. In a crossover trial involving 90 patients with type
2 diabetes, researchers also found that "cilnidipine, the only N/L-type
calcium channel
blocker (CCB) that is available at present, manifests its
antialbuminuric effect rapidly after switching treatment from an L-type
CCB."
No comments:
Post a Comment